Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function

Therapeutic targeting of inhibitory checkpoint molecules in combination with chimeric antigen receptor (CAR) T cells is currently investigated in a variety of clinical studies for treatment of hematologic and solid malignancies. However, the impact of co-inhibitory axes and their therapeutic implica...

Descripción completa

Detalles Bibliográficos
Autores principales: Blaeschke, Franziska, Ortner, Eva, Stenger, Dana, Mahdawi, Jasmin, Apfelbeck, Antonia, Habjan, Nicola, Weißer, Tanja, Kaeuferle, Theresa, Willier, Semjon, Kobold, Sebastian, Feuchtinger, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018974/
https://www.ncbi.nlm.nih.gov/pubmed/35464394
http://dx.doi.org/10.3389/fimmu.2022.845499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018974/
https://www.ncbi.nlm.nih.gov/pubmed/35464394
http://dx.doi.org/10.3389/fimmu.2022.845499

Ejemplares similares